Sulphasalazine inhibits human antigen-specific immune responses in vivo
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
MetadataShow full item record
CitationAnn. Rheum. Dis. 2007, 66(4):481-5
AbstractOBJECTIVE: To study the effects of the antirheumatic drug sulphasalazine (SASP) on the immune system by analysing systemic and gut-associated immune responses. METHODS: A total of 23 healthy volunteers were treated with either SASP or placebo for 5 weeks in a double-blind fashion and immunised 2 weeks after the initiation of treatment. Specific immune responses were triggered by subcutaneous immunisation with tetanus toxoid and by peroral immunisation with inactivated influenza vaccine. The effects of treatment on specific immunity to tetanus and influenza were evaluated by enzyme-linked immunospot assay quantifying the number of circulating specific and total antibody-producing cells (spot-forming cells (SFC)) at 6, 8 and 10 days after immunisation. RESULTS: An immunosuppressive effect of SASP on systemic immune response was observed with a decrease in the total number of IgG-SFC, IgG anti-tetanus SFC and IgG anti-tetanus antibody levels in serum. SASP also exerted an immunosuppressive effect on the mucosa-associated immune system as seen from its down-regulating effect on the total number of circulating IgA SFC. CONCLUSIONS: These data show firstly that SASP exerts an immunosuppressive effect on defined immune responses to immunisation in vivo, and secondly that both mucosa-associated and systemic immunity are affected by SASP treatment.
DescriptionTo access publisher full text version of this article. Please click on the hyperlink in Additional Links field
- Pneumococcal conjugate vaccination in toddlers: mucosal antibody response measured as circulating antibody-secreting cells and as salivary antibodies.
- Authors: Nieminen T, Käyhty H, Leroy O, Eskola J
- Issue date: 1999 Sep
- Specific IgA subclass responses in serum and saliva: a 12-month follow-up study after parenteral booster immunization with tetanus toxoid.
- Authors: Engström PE, Gustafson R, Granberg M, Engström GN
- Issue date: 2002 Aug
- Pneumococcal conjugate vaccination in adults: circulating antibody secreting cell response and humoral antibody responses in saliva and in serum.
- Authors: Nieminen T, Eskola J, Käyhty H
- Issue date: 1998 Apr
- Passive transfer of maternal immunoglobulin isotype antibodies against tetanus and influenza and their effect on the response of foals to vaccination.
- Authors: Wilson WD, Mihalyi JE, Hussey S, Lunn DP
- Issue date: 2001 Nov
- Time course of antibody response to tetanus toxoid and pneumococcal capsular polysaccharides in patients infected with HIV.
- Authors: Talesnik E, Vial PA, Labarca J, Méndez C, Soza X
- Issue date: 1998 Dec 15